Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in ...

PepsiCo is steadfast on its long-term growth target despite falling short in 2024, with an emphasis on better-for-you in ...

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

As more research is published about the health benefits associated with GLP-1s, like sleep apnea, heart disease, and ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...